OFIX

SEC source: 0001209191-20-023332 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,675

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023323 · doc4.xml · derivative · entry 4

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,996

Underlying: Common Stock · 26,996 shares

Expires 2030-04-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023323 · doc4.xml · nonDerivative · entry 2

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,344

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023323 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,912

SEC source: 0001209191-20-023315 · doc4.xml · derivative · entry 4

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,223

Underlying: Common Stock · 28,223 shares

Expires 2030-04-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023315 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,999

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023315 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,183

SEC source: 0001209191-20-023302 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,372

Underlying: Common Stock · 107,372 shares

Expires 2030-04-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-023302 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,266

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 1, 2020.

SEC source: 0001209191-20-019880 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,939

SEC source: 0001209191-20-019080 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,574

F1 · shares: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.58 to $27.23, inclusive. The reporting person undertakes to provide Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-20-014262 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,728

F1 · shares: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.23 to $35.50, inclusive. The reporting person undertakes to provide Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-19-059335 · doc4.xml · derivative · entry 2

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,395

Underlying: Common Stock · 33,395 shares

Expires 2029-12-04

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, December 4, 2019.

SEC source: 0001209191-19-059335 · doc4.xml · nonDerivative · entry 1

Kenny Kevin J. · CIK 0001520400 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,009

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, December 4, 2019.

SEC source: 0001209191-19-055270 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,449

Underlying: Common Stock · 81,449 shares

Expires 2029-11-01

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, November 1, 2019.

SEC source: 0001209191-19-055270 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,828

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, November 1, 2019.

SEC source: 0001209191-19-054878 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,899

F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements related to the vesting of restricted stock.

SEC source: 0001209191-19-054868 · doc4.xml · nonDerivative · entry 3

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,100

SEC source: 0001209191-19-054868 · doc4.xml · nonDerivative · entry 2

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,000

SEC source: 0001209191-19-054868 · doc4.xml · nonDerivative · entry 1

MATRICARIA RONALD A · CIK 0001221872 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,800

SEC source: 0001209191-19-050987 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,499

SEC source: 0001209191-19-049463 · doc4.xml · nonDerivative · entry 1

Hinrichs James F. · CIK 0001506974 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,023

SEC source: 0001209191-19-048742 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,049

SEC source: 0001209191-19-047732 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,041

F1 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.50 to $51.09, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

SEC source: 0001209191-19-044717 · doc4.xml · derivative · entry 2

Serbousek Jon Carl · CIK 0001536875 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,711

Underlying: Common Stock · 50,711 shares

Expires 2029-08-05

F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, August 5, 2019.

SEC source: 0001209191-19-044717 · doc4.xml · nonDerivative · entry 1

Serbousek Jon Carl · CIK 0001536875 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,743

F1 · shares: Represents time-based vesting restricted stock units that vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, August 5, 2019.

SEC source: 0001209191-19-042100 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,846

SEC source: 0001209191-19-042100 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,339

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 4

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,970

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 3

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,263

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,557

SEC source: 0001209191-19-042104 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,876

SEC source: 0001209191-19-042102 · doc4.xml · nonDerivative · entry 3

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,169

SEC source: 0001209191-19-042102 · doc4.xml · nonDerivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,542

SEC source: 0001209191-19-042102 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,919

SEC source: 0001209191-19-042095 · doc4.xml · nonDerivative · entry 1

Elting Kimberley A. · CIK 0001605209 · Chief Legal & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,414

SEC source: 0001209191-19-042097 · doc4.xml · nonDerivative · entry 3

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,617

SEC source: 0001209191-19-042097 · doc4.xml · nonDerivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,980

SEC source: 0001209191-19-042097 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,375

SEC source: 0001209191-19-041724 · doc4.xml · derivative · entry 2

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,937 shares

Expires 2019-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On July 1, 2016, the reporting person was granted 7,875 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,937 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041724 · doc4.xml · nonDerivative · entry 1

DOUG RICE · CIK 0001618861 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On July 1, 2016, the reporting person was granted 7,875 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,937 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041722 · doc4.xml · derivative · entry 2

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,330 shares

Expires 2019-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On July 1, 2016, the reporting person was granted 6,660 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,330 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041722 · doc4.xml · nonDerivative · entry 1

NIEMANN BRADLEY V. · CIK 0001669839 · President of Global Spine

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,239

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On July 1, 2016, the reporting person was granted 6,660 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,330 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041720 · doc4.xml · derivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,150 shares

Expires 2019-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On July 1, 2016, the reporting person was granted 36,300 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 18,150 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041720 · doc4.xml · nonDerivative · entry 1

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On July 1, 2016, the reporting person was granted 36,300 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 18,150 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041718 · doc4.xml · derivative · entry 2

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,625 shares

Expires 2019-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On July 1, 2016, the reporting person was granted 7,250 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,625 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041718 · doc4.xml · nonDerivative · entry 1

Finegan Michael · CIK 0001391402 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,827

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On July 1, 2016, the reporting person was granted 7,250 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,625 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041716 · doc4.xml · derivative · entry 2

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,330 shares

Expires 2019-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: On July 1, 2016, the reporting person was granted 6,660 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,330 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-041716 · doc4.xml · nonDerivative · entry 1

Bianchi Davide · CIK 0001587881 · President, Global Extremities

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,526

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On July 1, 2016, the reporting person was granted 6,660 performance stock units that, to the extent earned, settle as common stock based on the Company's total shareholder return ("TSR"), in relation to the TSR of companies included within the S&P Healthcare Select Sector Index as of July 1, 2016, during the performance period of July 1, 2016 through June 28, 2019. On July 8, 2019 (the "Vesting Date"), the compensation committee of the Company's board of directors determined that the awards were achieved at 50% of target, resulting in 3,330 shares of common stock being earned by the reporting person. Under the terms of the award, delivery of the earned shares of common stock will be deferred until one year following the Vesting Date.

SEC source: 0001209191-19-037407 · doc4.xml · nonDerivative · entry 2

Mason Brad · CIK 0001572153 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,930

F1 · kind: The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019.

F3 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.315 to $51.91, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.